睿知中国疾病研究地图
候选清单0

重庆重庆医科大学

重庆医科大学附属第二医院

Second Affiliated Hospital of Chongqing Medical University

在本站收录的 53 种疾病中,这家医院列在其中 21 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

这家医院的官网还没有核对。

联系这家医院

重庆医科大学附属第二医院的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 食管鳞状细胞癌Oesophageal squamous cell carcinoma10 篇牵头论文
  2. 肝细胞癌Hepatocellular carcinoma108 篇牵头论文
  3. 胃癌Stomach cancer23 篇牵头论文
  4. 视网膜母细胞瘤Retinoblastoma5 篇牵头论文
  5. 骨肉瘤Osteosarcoma7 篇牵头论文
  6. 胃肠道间质瘤Gastrointestinal stromal tumour4 篇牵头论文
  7. 神经母细胞瘤Neuroblastoma2 篇牵头论文
  8. 尤文肉瘤Ewing sarcoma1 篇牵头论文
  9. 再生障碍性贫血Aplastic anaemia2 篇牵头论文
  10. 噬血细胞性淋巴组织细胞增生症Haemophagocytic lymphohistiocytosis2 篇牵头论文
  11. 血友病 AHaemophilia A1 篇牵头论文
  12. 血栓性血小板减少性紫癜Thrombotic thrombocytopenic purpura2 篇牵头论文
  13. 范可尼贫血Fanconi anaemia1 篇牵头论文
  14. 大动脉炎Takayasu arteritis1 篇牵头论文
  15. 肝包虫病Hepatic echinococcosis1 篇牵头论文
  16. 特发性肺纤维化Idiopathic pulmonary fibrosis1 篇牵头论文
  17. 肌萎缩侧索硬化症Amyotrophic lateral sclerosis1 篇牵头论文
  18. 白塞病Behçet disease1 篇牵头论文
  19. IgA 肾病IgA nephropathy1 篇牵头论文
  20. 尼曼-匹克病 C 型Niemann–Pick disease type C1 篇牵头论文
  21. 原发性胆汁性胆管炎Primary biliary cholangitis0 篇牵头论文

未列出的收录疾病:鼻咽癌、肝母细胞瘤、脊索瘤、多发性骨髓瘤、B 细胞急性淋巴细胞白血病、β 地中海贫血、非典型溶血性尿毒症综合征、视神经脊髓炎谱系疾病、IgG4相关性疾病、重症肌无力、烟雾病、肝豆状核变性、胆道闭锁、抗 NMDA 受体脑炎、肺淋巴管平滑肌瘤病、脊髓性肌萎缩症、法布雷病、庞贝病、杜氏肌营养不良、Alport 综合征、戈谢病、成骨不全症、原发性硬化性胆管炎、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、家族性腺瘤性息肉病、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

食管鳞状细胞癌

Oesophageal squamous cell carcinoma

2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 10 篇,占 0.3%。

牵头论文
10
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 1120232024: 4420242025: 332025

重庆有 7 家医院列在食管鳞状细胞癌下全国有 191 家医院列在食管鳞状细胞癌下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的食管鳞状细胞癌开放试验。

这些数字背后的记录
研究主题影像与人工智能新辅助与综合治疗免疫治疗
论文中的科室影像/核医学科消化/肝病科
牵头的论文10
  1. MRI based fractal analysis of esophageal squamous cell carcinoma to preoperatively predict lymphnode metastasis.2026European journal of radiology
  2. Preoperative identification of small metastatic lymph nodes in esophageal squamous cell carcinoma using CT radiomics of lymph nodes.2025Abdominal radiology (New York)
  3. Adjuvant immunotherapy in esophageal squamous cell carcinoma after radiotherapy: retrospective multicentric survival analysis.2025Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  4. Transcription factor SPI1 exacerbates the malignant progression of esophageal squamous cell carcinoma byactivating LAMA3 expression.2025General physiology and biophysics
  5. Contrast-enhanced CT radiomics features to preoperatively identify differences between tumor and proximal tumor-adjacent and tumor-distant tissues of resectable esophageal squamous cell carcinoma.2024Cancer imaging : the official publication of the International Cancer Imaging Society免费全文
  6. Baseline CT radiomics features to predict pathological complete response of advanced esophageal squamous cell carcinoma treated with neoadjuvant chemotherapy using paclitaxel and cisplatin.2024European journal of radiology
  7. Preoperative CT radiomics of esophageal squamous cell carcinoma and lymph node to predict nodal disease with a high diagnostic capability.2024European journal of radiologyRCT
  8. Association between sulfur microbial diet and the risk of esophageal cancer: a prospective cohort study in 101,752 American adults.2024Nutrition journal免费全文
  9. Fusobacterium nucleatum promotes the early occurrence of esophageal cancer through upregulation of IL-32/PRTN3 expression.2023Cancer science免费全文
  10. Toxic epidermal necrolysis during camrelizumab treatment for esophageal squamous cell carcinoma.2022Contact dermatitis
PubMed 以外找到的论文(未计入)1
  1. Additional file 1 of OTUB2 Regulates YAP1/TAZ to Promotes the Progression of Esophageal Squamous Cell Carcinoma2022Figshare数据集

打开 PubMed 检索ClinicalTrials.gov

癌症

肝细胞癌

Hepatocellular carcinoma

2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 108 篇,占 0.7%。

牵头论文
108
2021–2025 年
牵头试验
5
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 212120212022: 161620222023: 272720232024: 222220242025: 18182025

重庆有 5 家医院列在肝细胞癌下全国有 192 家医院列在肝细胞癌下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 即将招募
    Surgery vs. Watch-and-Wait Strategy in Complete Responders for Hepatocellular Carcinoma
    分期
    不分期
    开始
    2026-12
    登记号
    NCT07866612

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:四川大学华西医院;另有 8 家列出的医院为研究中心上海、北京、南京、广州、成都、福州、重庆

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题复发与预后影像、人工智能与早期发现乙肝与肝硬化
论文中的科室普外/肝胆胰外科消化/肝病科病理/检验科影像/核医学科

这些论文过半是实验室或动物研究。

牵头的论文108
  1. O-GlcNAcylation of DDX46 promotes hepatocellular carcinoma progression by activating the PI3K/Akt signaling pathway.2026Biochimica et biophysica acta. Molecular cell research
  2. MASTL Promotes Hepatocellular Carcinoma Progression and Paclitaxel Resistance Through Mitotic Catastrophe.2026Cancer science免费全文
  3. Acetyl-coenzyme A synthetase 2-mediated acetyl-coenzyme A accumulation promotes mitophagy and tumor growth via increased H3K27ac in hepatitis B virus-related hepatocellular carcinoma.2026Clinical and molecular hepatology免费全文
  4. Contrast-enhanced MRI-based multi-parameter habitats radiomics models to predict early recurrence in early-stage hepatocellular carcinoma following curative resection.2026European journal of radiology
  5. RPL6 Interacts with HMGCS1 to Stabilize HIF-1α by Promoting Cholesterol Production in Hepatocellular Carcinoma.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  6. Targeting FDFT1 Reduces Cholesterol and Bile Acid Production and Delays Hepatocellular Carcinoma Progression Through the HNF4A/ALDOB/AKT1 Axis.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  7. Dietary monounsaturated fatty acid facilitates lipid droplet turnover through chaperone HSP90A-mediated lysosomal degradation of PLIN2 in hepatocellular carcinoma.2025Autophagy免费全文
  8. Hypoxia reduces SLC27A5 to promote hepatocellular carcinoma proliferation by repressing HNF4A.2025Biochimica et biophysica acta. Molecular cell research
  9. SNRPA promotes hepatocellular carcinoma proliferation and lenvatinib resistance via B7-H6-STAT3/AKT axis by facilitating B7-H6 pre-mRNA maturation.2025Bioscience trends
  10. SPOP Suppresses Hepatocellular Carcinoma Growth and Metastasis by Ubiquitination and Proteasomal Degradation of TRAF6.2025Cancer science免费全文
  11. GFAT1 promotes the progression of hepatocellular carcinoma via enhancing the O-GlcNAcylation of VEZF1.2025Cell death & disease免费全文
  12. O-GlcNAcylation of METTL3 drives hepatocellular carcinoma progression by upregulating MCM10 expression in an m6A-IGF2BP3-dependent manner.2025Cell death & disease免费全文
  13. LncRNA DERCNC in Hepatocellular Carcinoma with Cirrhosis Aggravates Tumor Proliferation by Targeting SOX9.2025Current cancer drug targets
  14. Predicting postresection outcomes in solitary small hepatocellular carcinoma via pretreatment MR imaging features: subgroup analysis according to alpha-fetoprotein expression.2025European radiology
  15. Genotype 3 is linked to worse liver disease progression in hepatitis C patients even after SVR following DAA therapy.2025Frontiers in cellular and infection microbiology免费全文
  16. Integrating bioinformatics and experimental validation to reveal a novel VRK score as a prognostic and therapeutic biomarker in hepatocellular carcinoma.2025Frontiers in immunology免费全文
  17. Immunoregulatory function and anticancer effects of Polygonatum sibiricum polysaccharides against hepatic carcinoma via macrophage phenotype modulation.2025International journal of biological macromolecules
  18. Neutrophil-macrophage crosstalk via NETs-IL-17/VEGF/S100A9 axis promotes hepatocellular carcinoma progression.2025Journal of experimental & clinical cancer research : CR免费全文
  19. Diagnostic value of TAP, PIVKA-II, and AFP in hepatocellular carcinoma and their prognostic value for patients treated with transarterial chemoembolization.2025Laboratory medicine
  20. Phosphoglycerate dehydrogenase stabilizes protein kinase C delta type mRNA to promote hepatocellular carcinoma progression.2025Signal transduction and targeted therapy免费全文
  21. Biomimetic Dual-Engine Nanodisruptor Degrades Extracellular Matrix and Hijacks TAM2 to Unlock Deep Immune Infiltration in HCC.2025Small (Weinheim an der Bergstrasse, Germany)
  22. A nomogram based on PNI and preoperative TACE can predict overall survival in patients with larger than 2 cm HCC after hepatectomy.2025Updates in surgery
  23. Metabolic Enzyme SLC27A5 Regulates PIP4K2A pre-mRNA Splicing as a Noncanonical Mechanism to Suppress Hepatocellular Carcinoma Metastasis.2024Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  24. Loss of LRP1 Promotes Hepatocellular Carcinoma Progression via UFL1-Mediated Activation of NF-κB Signaling.2024Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  25. Loss of Carbamoyl Phosphate Synthetase 1 Potentiates Hepatocellular Carcinoma Metastasis by Reducing Aspartate Level.2024Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  26. Impact of preoperative transcatheter arterial chemoembolization (TACE) on postoperative long-term survival in patients with nonsmall hepatocellular carcinoma: a propensity score matching analysis.2024BMC cancer免费全文
  27. Systemic loss of CD36 aggravates NAFLD-related HCC through MEK1/2-ERK1/2 signaling pathway.2024Biochemical and biophysical research communications
  28. Analysis of clinical significance and molecular characteristics of methionine metabolism and macrophage-related patterns in hepatocellular carcinoma based on machine learning.2024Cancer biomarkers : section A of Disease markers免费全文
  29. PD-L1+ neutrophils induced NETs in malignant ascites is a potential biomarker in HCC.2024Cancer immunology, immunotherapy : CII免费全文
  30. Inhibiting cholesterol de novo synthesis promotes hepatocellular carcinoma progression by upregulating prostaglandin E synthase 2-mediated arachidonic acid metabolism under high fatty acid conditions.2024Cancer science免费全文
  31. Controlling Nutritional Status (CONUT) Score is Associated with Overall Survival in Patients with Hepatocellular Carcinoma Treated with Conventional Transcatheter Arterial Chemoembolization: A Propensity Score Matched Analysis.2024Cardiovascular and interventional radiology
  32. m6A demethylation of FOSL1 mRNA protects hepatoma cells against necrosis under glucose deprivation.2024Cell death and differentiation免费全文
  33. Non-canonical function of PHGDH promotes HCC metastasis by interacting with METTL3.2024Cellular oncology (Dordrecht, Netherlands)免费全文
  34. Development and validation of a model for predicting who can benefit from multiple TACE in HCC patients.2024Clinical and experimental medicine免费全文
  35. Prediction of microvascular invasion and pathological differentiation of hepatocellular carcinoma based on a deep learning model.2024European journal of radiology
  36. Non-linear association of baseline viral load with on-treatment hepatocellular carcinoma risk in chronic hepatitis B: still needs further discussion.2024Gut
  37. Letter to the Editor: Chronic hepatitis B baseline viral load and on-treatment liver cancer risk-A multinational cohort study of HBeAg-positive patients.2024Hepatology (Baltimore, Md.)
  38. Immunomodulatory effects of Fructus corni acidic polysaccharide and its selenium nanoparticles composites in hepatocellular carcinoma.2024International journal of biological macromolecules
  39. Anti-hepatoma immunotherapy of Pholiota adiposa polysaccharide-coated selenium nanoparticles by reversing M2-like tumor-associated macrophage polarization.2024International journal of biological macromolecules
  40. Smart responsive Fe/Mn nanovaccine triggers liver cancer immunotherapy via pyroptosis and pyroptosis-boosted cGAS-STING activation.2024Journal of nanobiotechnology免费全文
  41. Mito-LND and (E)-Akt inhibitor-IV: novel compounds inducing endoplasmic reticulum stress and ROS accumulation against hepatocellular carcinoma.2024Journal of translational medicine免费全文
  42. O-GlcNAcylation of E3 ubiquitin ligase SKP2 promotes hepatocellular carcinoma proliferation.2024Oncogene
  43. Combination of bulk RNA and single-cell sequencing unveils PANoptosis-related immunological ecology hallmarks and classification for clinical decision-making in hepatocellular carcinoma.2024Scientific reports免费全文
  44. Metadherin promotes stem cell phenotypes and correlated with immune infiltration in hepatocellular carcinoma.2024World journal of gastroenterology免费全文
  45. Peroxisomal trans-2-enoyl-CoA inhibits proliferation, migration and invasion of hepatocellular carcinoma cells.2023Acta histochemica
  46. P53/miR-34a/SIRT1 positive feedback loop regulates the termination of liver regeneration.2023Aging免费全文
  47. Laparoscopic Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy (L-ALPPS) After Conversion Therapy for BCLC-B Hepatocellular Carcinoma: A Video Article.2023Annals of surgical oncology
  48. Transradial versus transfemoral approach for TACE: a retrospective study.2023BMC gastroenterology免费全文
  49. Elevated neutrophil extracellular traps by HBV-mediated S100A9-TLR4/RAGE-ROS cascade facilitate the growth and metastasis of hepatocellular carcinoma.2023Cancer communications (London, England)免费全文
  50. Transcriptional regulation of NDUFA4L2 by NFIB induces sorafenib resistance by decreasing reactive oxygen species in hepatocellular carcinoma.2023Cancer science免费全文
  51. Programmed death ligand 1 regulates epithelial-mesenchymal transition and cancer stem cell phenotypes in hepatocellular carcinoma through the serum and glucocorticoid kinase 2/β-catenin signaling pathway.2023Cancer science免费全文
  52. SLC27A5 promotes sorafenib-induced ferroptosis in hepatocellular carcinoma by downregulating glutathione reductase.2023Cell death & disease免费全文
  53. High dietary fructose promotes hepatocellular carcinoma progression by enhancing O-GlcNAcylation via microbiota-derived acetate.2023Cell metabolism
  54. Circulating sNinj1 as a novel predictor of prognosis and severity in hepatocellular carcinoma.2023Clinica chimica acta; international journal of clinical chemistry
  55. Identification of a novel plasma metabolite panel as diagnostic biomarker for hepatocellular carcinoma.2023Clinica chimica acta; international journal of clinical chemistry
  56. Efficacy of Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus: A Systematic Review and Meta-Analysis.2023Current oncology (Toronto, Ont.)免费全文
  57. Deep learning-assisted LI-RADS grading and distinguishing hepatocellular carcinoma (HCC) from non-HCC based on multiphase CT: a two-center study.2023European radiology
  58. Portal vein tumour thrombosis radiotherapy improves the treatment outcomes of immunotherapy plus bevacizumab in hepatocellular carcinoma: a multicentre real-world analysis with propensity score matching.2023Frontiers in immunology免费全文
  59. Laparoscopic liver resection for hepatocellular carcinoma complicated with significant portal hypertension: A propensity score-matched survival analysis.2023Hepatobiliary & pancreatic diseases international : HBPD INT
  60. Circular RNA hsa_circ_0000519 contributes to angiogenesis and tumor progression in hepatocellular carcinoma through the miR-1296/E2F7 axis.2023Human cell
  61. Prognostic significance of psoas muscle index in male hepatocellular carcinoma patients treated with immune checkpoint inhibitors and tyrosine kinase inhibitors.2023Human vaccines & immunotherapeutics免费全文
  62. High-intensity focused ultrasound versus transarterial chemoembolization for hepatocellular carcinoma: a meta-analysis.2023International journal of radiation biology
  63. Integrative analysis reveals that SLC38A1 promotes hepatocellular carcinoma development via PI3K/AKT/mTOR signaling via glutamine mediated energy metabolism.2023Journal of cancer research and clinical oncology免费全文
  64. A novel nomogram based on the hematological prognosis risk scoring system can predict the overall survival of patients with hepatocellular carcinoma.2023Journal of cancer research and clinical oncology免费全文
  65. VEGF/Nrp1/HIF-1α promotes proliferation of hepatocellular carcinoma through a positive feedback loop.2023Medical oncology (Northwood, London, England)
  66. Lysyl hydroxylase LH1 promotes confined migration and metastasis of cancer cells by stabilizing Septin2 to enhance actin network.2023Molecular cancer免费全文
  67. O-GlcNAcylation of SPOP promotes carcinogenesis in hepatocellular carcinoma.2023Oncogene
  68. Liver fibrosis-derived exosomal miR-106a-5p facilitates the malignancy by targeting SAMD12 and CADM2 in hepatocellular carcinoma.2023PloS one免费全文
  69. ANXA10 is a prognostic biomarker and suppressor of hepatocellular carcinoma: a bioinformatics analysis and experimental validation.2023Scientific reports免费全文
  70. O-GlcNAcylation of YTHDF2 promotes HBV-related hepatocellular carcinoma progression in an N6-methyladenosine-dependent manner.2023Signal transduction and targeted therapy免费全文
  71. Identification of a diketopiperazine-based O-GlcNAc transferase inhibitor sensitizing hepatocellular carcinoma to CDK9 inhibition.2023The FEBS journal
  72. A theranostic metallodrug modulates immunovascular crosstalk to combat immunosuppressive liver cancer.2022Acta biomaterialia
  73. Identification of alanine aminotransferase 1 interaction network via iTRAQ-based proteomics in alternating migration, invasion, proliferation and apoptosis of HepG2 cells.2022Aging免费全文
  74. LINC02154 promotes the proliferation and metastasis of hepatocellular carcinoma by enhancing SPC24 promoter activity and activating the PI3K-AKT signaling pathway.2022Cellular oncology (Dordrecht, Netherlands)免费全文
  75. Dysregulated glucuronic acid metabolism exacerbates hepatocellular carcinoma progression and metastasis through the TGFβ signalling pathway.2022Clinical and translational medicine免费全文
  76. circKCNN2 suppresses the recurrence of hepatocellular carcinoma at least partially via regulating miR-520c-3p/methyl-DNA-binding domain protein 2 axis.2022Clinical and translational medicine免费全文
  77. Green synthesized gold nanoparticles from Pseudobulbus Cremastrae seu Pleiones show efficacy against hepatic carcinoma potentially through immunoregulation.2022Drug delivery免费全文
  78. PCDH17 is regulated by methylation of DNMT3B and affects the malignant biological behavior of HCC through EMT.2022Experimental cell research
  79. High platelet count predicts poor prognosis in HCC patients undergoing TACE: a propensity score-matched analysis.2022Expert review of gastroenterology & hepatology
  80. ALKBH5/MAP3K8 axis regulates PD-L1+ macrophage infiltration and promotes hepatocellular carcinoma progression.2022International journal of biological sciences免费全文
  81. Evaluating the long-term survival benefits of high intensity focused ultrasound ablation for hepatocellular carcinoma with portal vein tumor thrombus: a single center retrospective study.2022International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  82. Cholesterol sensor SCAP contributes to sorafenib resistance by regulating autophagy in hepatocellular carcinoma.2022Journal of experimental & clinical cancer research : CR免费全文
  83. Molecular mechanism of albumin in suppressing invasion and metastasis of hepatocellular carcinoma.2022Liver international : official journal of the International Association for the Study of the Liver免费全文
  84. Identification of G6PC as a potential prognostic biomarker in hepatocellular carcinoma based on bioinformatics analysis.2022Medicine免费全文
  85. miR-550a-5p promotes the proliferation and migration of hepatocellular carcinoma by targeting GNE via the Wnt/β-catenin signaling pathway.2022Neoplasma
  86. Salivary orosomucoid 1 as a biomarker of hepatitis B associated hepatocellular carcinoma.2022Scientific reports免费全文
  87. CK1α upregulates the IFNAR1 expression to prompt the anti-HBV effect of type I IFN in hepatoma carcinoma cells.2022Virologica Sinica免费全文
  88. No difference in hepatocellular carcinoma risk in chronic hepatitis B patients treated with tenofovir vs entecavir: evidence from an updated meta-analysis.2021Aging免费全文
  89. Anticancer Effect of Rh2, a Histone Deacetylase Inhibitor, in HepG2 Cells and HepG2 Cell-Derived Xenograft Tumors Occurs via the Inhibition of HDACs and Activation of the MAPK Signaling Pathway.2021Asian Pacific journal of cancer prevention : APJCP免费全文
  90. Identification and Validation of a Prognostic Model Based on Three Autophagy-Related Genes in Hepatocellular Carcinoma.2021BioMed research international免费全文
  91. The role of CD133 in hepatocellular carcinoma.2021Cancer biology & therapy免费全文
  92. Systematic analysis of immune-related genes based on a combination of multiple databases to build a diagnostic and a prognostic risk model for hepatocellular carcinoma.2021Cancer immunology, immunotherapy : CII免费全文
  93. Normal tissue adjacent to tumor expression profile analysis developed and validated a prognostic model based on Hippo-related genes in hepatocellular carcinoma.2021Cancer medicine免费全文
  94. GSTZ1 sensitizes hepatocellular carcinoma cells to sorafenib-induced ferroptosis via inhibition of NRF2/GPX4 axis.2021Cell death & disease免费全文
  95. Circular RNA hsa_circ_101555 promotes hepatocellular carcinoma cell proliferation and migration by sponging miR-145-5p and regulating CDCA3 expression.2021Cell death & disease免费全文
  96. The fatty acid receptor CD36 promotes HCC progression through activating Src/PI3K/AKT axis-dependent aerobic glycolysis.2021Cell death & disease免费全文
  97. GASC1 promotes hepatocellular carcinoma progression by inhibiting the degradation of ROCK2.2021Cell death & disease免费全文
  98. Ubiquitin-specific protease 2a promotes hepatocellular carcinoma progression via deubiquitination and stabilization of RAB1A.2021Cellular oncology (Dordrecht, Netherlands)免费全文
  99. Epigenetic silencing of GCH1promotes hepatocellular carcinoma growth by activating superoxide anion-mediated ASK1/p38 signaling via inhibiting tetrahydrobiopterin de novo biosynthesis.2021Free radical biology & medicine
  100. A Web-Based Prediction Model for Cancer-Specific Survival of Elderly Patients With Early Hepatocellular Carcinoma: A Study Based on SEER Database.2021Frontiers in public healthRCT免费全文
  101. iRGD Peptide-Mediated Liposomal Nanoparticles with Photoacoustic/Ultrasound Dual-Modality Imaging for Precision Theranostics Against Hepatocellular Carcinoma.2021International journal of nanomedicine免费全文
  102. RAB27A-dependent release of exosomes by liver cancer stem cells induces Nanog expression in their differentiated progenies and confers regorafenib resistance.2021Journal of gastroenterology and hepatology
  103. C2orf40 inhibits hepatocellular carcinoma through interaction with UBR5.2021Journal of gastroenterology and hepatology
  104. Bioinformatics analysis of constructing a HCV-related hepatocellular carcinoma miRNA-mRNA regulation network.2021Medicine免费全文
  105. Identification and validation of EPHX2 as a prognostic biomarker in hepatocellular carcinoma.2021Molecular medicine reports免费全文
  106. O-GlcNAc modified-TIP60/KAT5 is required for PCK1 deficiency-induced HCC metastasis.2021Oncogene免费全文
  107. TACE Combined with HIFU Versus Surgical Resection for Single Hepatocellular Carcinoma with Child-Pugh B Cirrhosis in Overall Survival and Progression-Free Survival: A Retrospective Study.2021Technology in cancer research & treatment免费全文
  108. Factors influencing the short-term and long-term survival of hepatocellular carcinoma patients with portal vein tumor thrombosis who underwent chemoembolization.2021World journal of gastroenterology免费全文
中文论文(未计入)7
  1. [Study of a nomogram model of gadoxetate disodium-enhanced magnetic resonance imaging for the preoperative diagnosis of proliferative hepatocellular carcinoma and its value].2025Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
  2. [Comparative study of ultra-high field diffusion-weighted MRI imaging between hepatocellular carcinoma and paracancerous, distant cancerous, and background liver tissues].2024Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
  3. [Research progress and prospects of the application of radiographic imaging in the precise diagnosis and treatment of hepatocellular carcinoma].2024Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
  4. [Study on F9 gene expression downregulation and its clinical value in hepatocellular carcinoma].2023Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
  5. [Research progress of compound injection of traditional Chinese medicine in the treatment of liver cancer].2022Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
  6. [Research status and challenges of low-level viremia in chronic hepatitis B].2021Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
  7. [Treatment and prevention of bile duct injury in hepatocellular carcinoma after transarterial chemoembolization].2021Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)8
  1. Effects of Esketamine on Acute Abdominal Pain After TACE in Patients With Hepatocellular Carcinoma状态不明NCT05670561牵头方IV期2023-01 启动
  2. Auxiliary Diagnosis of Liver Nodules Using cfDNA Whole-genome Signatures状态不明NCT05393102牵头方2022-05 启动
  3. Effect of Esketamine on Abdominal Pain During TACE-HAIC in Patients With Hepatocellular Carcinoma状态不明NCT05416073牵头方IV期2022-06 启动
  4. Prognostic Value of Liver Cancer CTCs Isolated by a Novel Microfluidic Platform状态不明NCT05242237牵头方2021-12 启动
  5. Effect of Nutritional Indices on the Prognosis of HCC Patients已完成NCT05635279牵头方(推断)2022-11 启动
  6. Surgery vs. Watch-and-Wait Strategy in Complete Responders for Hepatocellular Carcinoma即将招募NCT07866612研究中心不分期2026-12 启动
  7. A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)进行中,不再招募NCT04344158研究中心III期2020-08 启动
  8. A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC已完成NCT03764293研究中心III期2019-06 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胃癌

Stomach cancer

2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 23 篇,占 0.2%。

牵头论文
23
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 3320212022: 5520222023: 7720232024: 5520242025: 332025

重庆有 6 家医院列在胃癌下全国有 218 家医院列在胃癌下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的胃癌开放试验。

这些数字背后的记录
研究主题早期发现与内镜腹膜转移与晚期影像与人工智能
论文中的科室消化/肝病科普外/肝胆胰外科病理/检验科肿瘤内科
牵头的论文23
  1. Association between the red blood cell distribution width-to-albumin ratio and risk of colorectal and gastric cancers: a cross-sectional study using NHANES 2005-2018.2025BMC gastroenterology免费全文
  2. Early-onset gastric cancer global burden profile, trends, and contributors.2025Cancer biology & medicine免费全文
  3. Gastric Adenocarcinoma Resembling Submucosal Tumor: A Case Report.2025The American journal of case reports免费全文
  4. A novel combined therapeutic strategy of Nano-EN-IR@Lip mediated photothermal therapy and stem cell inhibition for gastric cancer.2024Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  5. RHBDD1 Promotes the Growth and Stemness Characteristics of Gastric Cancer Cells by Activating Wnt/β-catenin Signaling Pathway.2024Current stem cell research & therapy
  6. VEPH1 suppresses the progression of gastric cancer by regulating the Hippo-YAP signalling pathway.2024Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  7. CT radiomics based on the peritumoral adipose region of gastric adenocarcinoma for preoperative prediction of lymph node metastasis.2024European journal of radiology
  8. Exploring the mediating role of blood metabolites in the relationship between gut microbiota and gastric cancer risk: a Mendelian randomization study.2024Frontiers in cellular and infection microbiology免费全文
  9. Aquaporins in Digestive System.2023Advances in experimental medicine and biology
  10. The GLI2/CDH6 axis enhances migration, invasion and mitochondrial fission of stomach adenocarcinoma cells.2023Biochemical and biophysical research communications
  11. Balloon-assisted technique for endoscopic en bloc retrieval of a large gastric gastrointestinal stromal tumor specimen.2023Endoscopy免费全文
  12. Three-arm endoscopic mucosal resection for gastric adenocarcinoma of fundic gland type.2023Endoscopy免费全文
  13. Integration of endoscopic screening, magnification, and resection for early gastric cancer: advantages of underwater EMR (with video).2023Gastrointestinal endoscopy
  14. Metabolic-associated fatty liver disease and risk of esophagogastric cancer: a systematic review and meta-analysis.2023Japanese journal of clinical oncology
  15. Dimethyladenosine Transferase 1 Homolog Promotes Human Gastric Carcinoma Cell Proliferation and Inhibits Apoptosis via the AKT Pathway.2023The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology免费全文
  16. Establishment of a 10-gene prognostic model for gastric cancer based on the tumor immune microenvironment.2022Analytical biochemistry
  17. Comprehensive Analysis of the Immune Implication of AKAP12 in Stomach Adenocarcinoma.2022Computational and mathematical methods in medicine免费全文
  18. Double-band ligation-assisted endoscopic submucosal resection for type 1 gastric neuroendocrine tumor with type A gastritis.2022Endoscopy
  19. Comprehensive analysis of the immune and prognostic implication of MASP1 in stomach adenocarcinoma.2022European review for medical and pharmacological sciences
  20. Knockdown of TRIM65 suppressed the proliferation and invasiveness of gastric cancer cells by restricting the ubiquitin degradation of PPM1A.2022Experimental cell research
  21. The transcription factor RUNX2 fuels YAP1 signaling and gastric cancer tumorigenesis.2021Cancer science免费全文
  22. Gastric metastasis and transformation of primary lung adenocarcinoma to small cell cancer after acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors: A case report.2021Medicine免费全文
  23. LAMB1 Is Related to the T Stage and Indicates Poor Prognosis in Gastric Cancer.2021Technology in cancer research & treatment免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
  1. Validating the Safety and Effectiveness of ENDOANGEL Upper Gastrointestinal Endoscope Image Auxiliary Diagnostic Software状态不明NCT05470452牵头方不分期2021-07 启动
  2. HFNO Reduces Hypoxia During Sedated Gastroscopy or Colonoscopy in High Risk Patients状态不明NCT05510388研究中心不分期2022-09 启动
  3. Predictive Effect of Abdominal Fat and Muscle Area Calculated Based on Abdominal CT on Gastric Cancer Patients状态不明NCT06606912研究中心2012-01 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

视网膜母细胞瘤

Retinoblastoma

2021–2025 年中国大陆作者发表的 301 篇视网膜母细胞瘤 PubMed 英文论文中,这家医院牵头了 5 篇,占 1.7%。

牵头论文
5
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 3320222023: 0020232024: 1120242025: 112025

重庆有 7 家医院列在视网膜母细胞瘤下全国有 196 家医院列在视网膜母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的视网膜母细胞瘤开放试验。

这些数字背后的记录
论文中的科室眼科/神经眼科病理/检验科

这些论文过半是实验室或动物研究。

打开 PubMed 检索ClinicalTrials.gov

癌症

骨肉瘤

Osteosarcoma

2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 7 篇,占 0.3%。

牵头论文
7
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 2220242025: 442025

重庆有 23 家医院列在骨肉瘤下全国有 742 家医院列在骨肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。

这些数字背后的记录
论文中的科室病理/检验科儿科

这些论文过半是实验室或动物研究。

牵头的论文7
  1. Protein Kinase Inhibitor Alpha Drives Vincristine Resistance in Ewing Sarcoma via cAMP-EPAC Signaling Reprogramming.2026Molecular carcinogenesis
  2. Genetically Engineered Glycosylphosphatidylinositol-Anchored Anti-GD2 Nanobody-Exosome Mimetics for Targeted Osteosarcoma Therapy In Vitro and In Vivo.2025ACS applied materials & interfaces
  3. An "Outer Piezoelectric and Inner Epigenetic" Logic-Gated PANoptosis for Osteosarcoma Sono-Immunotherapy and Bone Regeneration.2025Advanced materials (Deerfield Beach, Fla.)
  4. Structural characteristics of a fructan-type polysaccharide from Asparagus cochinchinensis rhizome and its anti-osteosarcoma activity mediated via macrophage polarization.2025International journal of biological macromolecules
  5. DCC-2036 inhibits osteosarcoma via targeting HCK and the PI3K/AKT-mTORC1 axis to promote autophagy.2025World journal of surgical oncology
  6. FOSL1 promotes stem cell‑like characteristics and anoikis resistance to facilitate tumorigenesis and metastasis in osteosarcoma by targeting SOX2.2024International journal of molecular medicine
  7. Advances on immunotherapy for osteosarcoma.2024Molecular cancer
早期论文(2016–2020 年)6
  1. A meta-analysis of prognostic factors of osteosarcoma.2020European review for medical and pharmacological sciences
  2. Multifunctional bone cement for synergistic magnetic hyperthermia ablation and chemotherapy of osteosarcoma.2020Materials science & engineering. C, Materials for biological applications
  3. Blocking the PD-1/PD-L1 axis enhanced cisplatin chemotherapy in osteosarcoma in vitro and in vivo.2019Environmental health and preventive medicine
  4. Efficacy Comparison of Six Chemotherapeutic Combinations for Osteosarcoma and Ewing's Sarcoma Treatment: A Network Meta-Analysis.2018Journal of cellular biochemistry
  5. miR‑494 inhibits cell proliferation and metastasis via targeting of CDK6 in osteosarcoma.2017Molecular medicine reports
  6. Tetrandrine inhibits the proliferation of human osteosarcoma cells by upregulating the PTEN pathway.2017Oncology reports

打开 PubMed 检索ClinicalTrials.gov

癌症

胃肠道间质瘤

Gastrointestinal stromal tumour

2021–2025 年中国大陆作者发表的 523 篇胃肠道间质瘤 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.8%。

牵头论文
4
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 2220232024: 0020242025: 222025

重庆有 11 家医院列在胃肠道间质瘤下全国有 261 家医院列在胃肠道间质瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的胃肠道间质瘤开放试验。

这些数字背后的记录
论文中的科室消化/肝病科

打开 PubMed 检索ClinicalTrials.gov

癌症

神经母细胞瘤

Neuroblastoma

2021–2025 年中国大陆作者发表的 1,132 篇神经母细胞瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.2%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

重庆有 10 家医院列在神经母细胞瘤下全国有 352 家医院列在神经母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。

这些数字背后的记录
论文中的科室影像/核医学科

打开 PubMed 检索ClinicalTrials.gov

癌症

尤文肉瘤

Ewing sarcoma

2021–2025 年中国大陆作者发表的 163 篇尤文肉瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.6%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

重庆有 5 家医院列在尤文肉瘤下全国有 139 家医院列在尤文肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的尤文肉瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

血液疾病

再生障碍性贫血

Aplastic anaemia

2021–2025 年中国大陆作者发表的 412 篇再生障碍性贫血 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.5%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 112025

重庆有 4 家医院列在再生障碍性贫血下全国有 63 家医院列在再生障碍性贫血下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的再生障碍性贫血开放试验。

这些数字背后的记录
研究主题免疫抑制治疗

打开 PubMed 检索ClinicalTrials.gov

血液疾病

噬血细胞性淋巴组织细胞增生症

Haemophagocytic lymphohistiocytosis

2021–2025 年中国大陆作者发表的 399 篇噬血细胞性淋巴组织细胞增生症 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.5%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 112025

重庆有 4 家医院列在噬血细胞性淋巴组织细胞增生症下全国有 66 家医院列在噬血细胞性淋巴组织细胞增生症下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的噬血细胞性淋巴组织细胞增生症开放试验。

这些数字背后的记录
研究主题遗传与家族性诊断与预后

打开 PubMed 检索ClinicalTrials.gov

血液疾病

血友病 A

Haemophilia A

2021–2025 年中国大陆作者发表的 272 篇血友病 A PubMed 英文论文中,这家医院牵头了 1 篇,占 0.4%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

重庆有 4 家医院列在血友病 A下全国有 160 家医院列在血友病 A下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的血友病 A开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

血液疾病

血栓性血小板减少性紫癜

Thrombotic thrombocytopenic purpura

2021–2025 年中国大陆作者发表的 64 篇血栓性血小板减少性紫癜 PubMed 英文论文中,这家医院牵头了 2 篇,占 3.1%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 1120242025: 002025

重庆有 3 家医院列在血栓性血小板减少性紫癜下全国有 59 家医院列在血栓性血小板减少性紫癜下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的血栓性血小板减少性紫癜开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

血液疾病

范可尼贫血

Fanconi anaemia

2021–2025 年中国大陆作者发表的 68 篇范可尼贫血 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.5%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

重庆有 2 家医院列在范可尼贫血下全国有 40 家医院列在范可尼贫血下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的范可尼贫血开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

大动脉炎

Takayasu arteritis

2021–2025 年中国大陆作者发表的 187 篇大动脉炎 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.5%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

重庆有 3 家医院列在大动脉炎下全国有 108 家医院列在大动脉炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的大动脉炎开放试验。

这些数字背后的记录
论文中的科室风湿免疫科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肝包虫病

Hepatic echinococcosis

2021–2025 年中国大陆作者发表的 152 篇肝包虫病 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.7%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

重庆有 2 家医院列在肝包虫病下全国有 49 家医院列在肝包虫病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肝包虫病开放试验。

这些数字背后的记录
论文中的科室影像/核医学科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

特发性肺纤维化

Idiopathic pulmonary fibrosis

2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.1%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

重庆有 6 家医院列在特发性肺纤维化下全国有 333 家医院列在特发性肺纤维化下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的特发性肺纤维化开放试验。

这些数字背后的记录
论文中的科室影像/核医学科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肌萎缩侧索硬化症

Amyotrophic lateral sclerosis

2021–2025 年中国大陆作者发表的 779 篇肌萎缩侧索硬化症 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.1%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

重庆有 6 家医院列在肌萎缩侧索硬化症下全国有 194 家医院列在肌萎缩侧索硬化症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肌萎缩侧索硬化症开放试验。

这些数字背后的记录
论文中的科室神经外科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

白塞病

Behçet disease

2021–2025 年中国大陆作者发表的 245 篇白塞病 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.4%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

重庆有 7 家医院列在白塞病下全国有 149 家医院列在白塞病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的白塞病开放试验。

这些数字背后的记录
论文中的科室眼科/神经眼科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgA 肾病

IgA nephropathy

2021–2025 年中国大陆作者发表的 736 篇IgA 肾病 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.1%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

重庆有 14 家医院列在IgA 肾病下全国有 346 家医院列在IgA 肾病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的IgA 肾病开放试验。

这些数字背后的记录
牵头的论文1
  1. Metabolomics study reveals blood biomarkers for early diagnosis of chronic kidney disease and IgA nephropathy: A retrospective cross-sectional study.2024Clinica chimica acta; international journal of clinical chemistry
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. A Study of Telitacicept for IgA Nephropathy (TELIGAN)进行中,不再招募NCT05799287研究中心III期2023-04 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

尼曼-匹克病 C 型

Niemann–Pick disease type C

2021–2025 年中国大陆作者发表的 16 篇尼曼-匹克病 C 型 PubMed 英文论文中,这家医院牵头了 1 篇,占 6.2%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

重庆有 1 家医院列在尼曼-匹克病 C 型下全国有 15 家医院列在尼曼-匹克病 C 型下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的尼曼-匹克病 C 型开放试验。

这些数字背后的记录
论文中的科室神经内科
牵头的论文1
  1. Niemann-Pick type C disease: Case report and review of the literature.2023Neuro endocrinology letters

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性胆汁性胆管炎

Primary biliary cholangitis

2021–2025 年没有牵头原发性胆汁性胆管炎的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头

重庆有 5 家医院列在原发性胆汁性胆管炎下全国有 173 家医院列在原发性胆汁性胆管炎下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
    分期
    III期
    开始
    2025-12
    登记号
    NCT07282353

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 35 家列出的医院为研究中心Baoji、上海、临沂、北京、十堰、南京、南宁、南昌、厦门、台州、合肥、哈尔滨、天津、成都、杭州、沈阳、深圳、湛江、福州、西安、郑州、重庆、长春、长沙、青岛

  2. 正在招募
    Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
    分期
    III期
    开始
    2023-09
    登记号
    NCT06051617

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 17 家列出的医院为研究中心上海、乌鲁木齐、北京、合肥、广州、成都、杭州、武汉、福州、西安、贵阳、郑州、重庆、长春

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
早期论文(2016–2020 年)2
  1. [Ursodeoxycholic acid combined with bezafibrate in the treatment of refractory primary biliary cholangitis: a meta-analysis].2019Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
  2. [Meta-analysis of anti-GP210 antibody and anti-SP100 antibody detection for diagnosis of primary biliary cirrhosis].2016Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA正在招募NCT07282353研究中心III期2025-12 启动
  2. Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis正在招募NCT06051617研究中心III期2023-09 启动

打开 PubMed 检索ClinicalTrials.gov

联系这家医院

出示给工作人员或司机的院名卡

重庆医科大学附属第二医院

Second Affiliated Hospital of Chongqing Medical University

重庆

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请在医院官网查询相关科室。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR
Second Affiliated Hospital of Chongqing Medical Univerity; Second Affiliated Hospital of Chongqing Medical; Second affiliated hospital of Chongqing Medical University; he Second Affiliated Hospital of Chongqing Medical University

提出更正下载数据